Targeting nucleotide metabolism: a promising approach to enhance cancer immunotherapy

被引:92
作者
Wu, Huai-liang [1 ]
Gong, Yue [1 ]
Ji, Peng [1 ]
Xie, Yi-fan [1 ]
Jiang, Yi-Zhou [1 ]
Liu, Guang-yu [1 ]
机构
[1] Fudan Univ, Shanghai Canc Ctr, Key Lab Breast Canc Shanghai, Dept Breast Surg,Dept Oncol, 270 Dongan Rd, Shanghai 200032, Peoples R China
关键词
INOSINE MONOPHOSPHATE DEHYDROGENASE; PURINE NUCLEOSIDE PHOSPHORYLASE; ACUTE LYMPHOBLASTIC-LEUKEMIA; ACUTE MYELOID-LEUKEMIA; I CLINICAL-TRIAL; CELL LUNG-CANCER; DIHYDROPYRIMIDINE DEHYDROGENASE; OPEN-LABEL; ADJUVANT CHEMOTHERAPY; T-CELLS;
D O I
10.1186/s13045-022-01263-x
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Targeting nucleotide metabolism can not only inhibit tumor initiation and progression but also exert serious side effects. With in-depth studies of nucleotide metabolism, our understanding of nucleotide metabolism in tumors has revealed their non-proliferative effects on immune escape, indicating the potential effectiveness of nucleotide antimetabolites for enhancing immunotherapy. A growing body of evidence now supports the concept that targeting nucleotide metabolism can increase the antitumor immune response by (1) activating host immune systems via maintaining the concentrations of several important metabolites, such as adenosine and ATP, (2) promoting immunogenicity caused by increased mutability and genomic instability by disrupting the purine and pyrimidine pool, and (3) releasing nucleoside analogs via microbes to regulate immunity. Therapeutic approaches targeting nucleotide metabolism combined with immunotherapy have achieved exciting success in preclinical animal models. Here, we review how dysregulated nucleotide metabolism can promote tumor growth and interact with the host immune system, and we provide future insights into targeting nucleotide metabolism for immunotherapeutic treatment of various malignancies.
引用
收藏
页数:21
相关论文
共 257 条
  • [1] CD73 IS INVOLVED IN LYMPHOCYTE BINDING TO THE ENDOTHELIUM - CHARACTERIZATION OF LYMPHOCYTE VASCULAR ADHESION PROTEIN-2 IDENTIFIES IT AS CD73
    AIRAS, L
    HELLMAN, J
    SALMI, M
    BONO, P
    PUURUNEN, T
    SMITH, DJ
    JALKANEN, S
    [J]. JOURNAL OF EXPERIMENTAL MEDICINE, 1995, 182 (05) : 1603 - 1608
  • [2] Nucleotide metabolism, oncogene-induced senescence and cancer
    Aird, Katherine M.
    Zhang, Rugang
    [J]. CANCER LETTERS, 2015, 356 (02) : 204 - 210
  • [3] Suppression of Nucleotide Metabolism Underlies the Establishment and Maintenance of Oncogene-Induced Senescence
    Aird, Katherine M.
    Zhang, Gao
    Li, Hua
    Tu, Zhigang
    Bitler, Benjamin G.
    Garipov, Azat
    Wu, Hong
    Wei, Zhi
    Wagner, Stephan N.
    Herlyn, Meenhard
    Zhang, Rugang
    [J]. CELL REPORTS, 2013, 3 (04): : 1252 - 1265
  • [4] The ectonucleotidases CD39 and CD73: Novel checkpoint inhibitor targets
    Allard, Bertrand
    Longhi, Maria Serena
    Robson, Simon C.
    Stagg, John
    [J]. IMMUNOLOGICAL REVIEWS, 2017, 276 (01) : 121 - 144
  • [5] Anti-CD73 therapy impairs tumor angiogenesis
    Allard, Bertrand
    Turcotte, Martin
    Spring, Kathleen
    Pommey, Sandra
    Royal, Isabelle
    Stagg, John
    [J]. INTERNATIONAL JOURNAL OF CANCER, 2014, 134 (06) : 1466 - 1473
  • [6] Targeting CD73 Enhances the Antitumor Activity of Anti-PD-1 and Anti-CTLA-4 mAbs
    Allard, Bertrand
    Pommey, Sandra
    Smyth, Mark J.
    Stagg, John
    [J]. CLINICAL CANCER RESEARCH, 2013, 19 (20) : 5626 - 5635
  • [7] Gemtuzumab Ozogamicin Versus Best Supportive Care in Older Patients With Newly Diagnosed Acute Myeloid Leukemia Unsuitable for Intensive Chemotherapy: Results of the Randomized Phase III EORTC-GIMEMA AML-19 Trial
    Amadori, Sergio
    Suciu, Stefan
    Selleslag, Dominik
    Aversa, Franco
    Gaidano, Gianluca
    Musso, Maurizio
    Annino, Luciana
    Venditti, Adriano
    Voso, Maria Teresa
    Mazzone, Carla
    Magro, Domenico
    De Fabritiis, Paolo
    Muus, Petra
    Alimena, Giuliana
    Mancini, Marco
    Hagemeijer, Anne
    Paoloni, Francesca
    Vignetti, Marco
    Fazi, Paola
    Meert, Liv
    Ramadan, Safaa Mahmoud
    Willemze, Roel
    de Witte, Theo
    Baron, Frederic
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (09) : 972 - +
  • [8] Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma
    Andtbacka, Robert H. I.
    Kaufman, Howard L.
    Collichio, Frances
    Amatruda, Thomas
    Senzer, Neil
    Chesney, Jason
    Delman, Keith A.
    Spitler, Lynn E.
    Puzanov, Igor
    Agarwala, Sanjiv S.
    Milhem, Mohammed
    Cranmer, Lee
    Curti, Brendan
    Lewis, Karl
    Ross, Merrick
    Guthrie, Troy
    Linette, Gerald P.
    Daniels, Gregory A.
    Harrington, Kevin
    Middleton, Mark R.
    Miller, Wilson H., Jr.
    Zager, Jonathan S.
    Ye, Yining
    Yao, Bin
    Li, Ai
    Doleman, Susan
    VanderWalde, Ari
    Gansert, Jennifer
    Coffin, Robert S.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (25) : 2780 - U98
  • [9] [Anonymous], 2019, Cancer Discov, V9, pOF1, DOI 10.1158/2159-8290.CD-NB2018-171
  • [10] Systemic Therapy for Locally Advanced and Metastatic Non-Small Cell Lung Cancer A Review
    Arbour, Kathryn C.
    Riely, Gregory J.
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2019, 322 (08): : 764 - 774